REFERENCES
1. Reilly AF, Lange BJ. Infections with viridans group streptococci in children with cancer. Pediatr Blood Cancer. 2007;49(6):774-780.
2. Lewis V, Yanofsky R, Mitchell D, et al. Predictors and outcomes of viridans group streptococcal infections in pediatric acute myeloid leukemia: from the Canadian infections in AML research group.Pediatr Infect Dis J. 2014;33(2):126-129.
3. Mikulska M, Viscoli C, Orasch C, et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients.The Journal of infection. 2014;68(4):321-331.
4. Persson L, Vikerfors T, Sjoberg L, Engervall P, Tidefelt U. Increased incidence of bacteraemia due to viridans streptococci in an unselected population of patients with acute myeloid leukaemia. Scand J Infect Dis. 2000;32(6):615-621.
5. Huang WT, Chang LY, Hsueh PR, et al. Clinical features and complications of viridans streptococci bloodstream infection in pediatric hemato-oncology patients. J Microbiol Immunol Infect.2007;40(4):349-354.
6. Ahmed R, Hassall T, Morland B, Gray J. Viridans Streptococcus bacteremia in children on chemotherapy for cancer: an under-estimated problem. Pediatr Haematol Oncol. 2003(20):439-444.
7. Gassas A, Grant R, Richardson S, et al. Predictors of viridans streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplant recipients. J Clin Oncol.2004;22(7):1222-1227.
8. Brunet AS, Ploton C, Galambrun C, et al. Low incidence of sepsis due to viridans streptococci in a ten-year retrospective study of pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2006;47(6):765-772.
9. Nielsen MJ, Claxton S, Pizer B, et al. Viridans Group Streptococcal Infections in Children After Chemotherapy or Stem Cell Transplantation: A 10-year Review From a Tertiary Pediatric Hospital. Medicine (Baltimore). 2016;95(9):e2952.
10. Salzer W, Dinndorf P, Dreyer Z, Hilden J, Reaman GH. Analysis of infectious complications in infants with acute lymphoblastic leukemia treated on the Children’s Cancer Group Protocol 1953: a report from the Children’s Oncology Group. J Pediatr Hematol Oncol.2009;31(6):398-405.
11. Martino R, Manteiga R, Sánchez I, et al. Viridans streptococcal shock syndrome during bone marrow transplantation. Acta Haematol.1995;94(2):69-73.
12. Bruckner L, Gigliotti F. Viridans group streptococcal infections among children with cancer and the importance of emerging antibiotic resistance. Semin Pediatr Infect Dis. 2006;17(3):153-160.
13. Adcock KG, Akins RL, Farrington EA. Evaluation of empiric vancomycin therapy in children with fever and neutropenia. Pharmacotherapy.1999;19(11):1315-1320.
14. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America.Clinical Infectious Diseases. 2011;52(4):e56-e93.
15. Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. J Clin Oncol. 2017;35(18):2082-2094.
16. Biomeriux. E-test product information. https://www.biomerieux.com.au/products/etestr. Published 2018. Updated May 2018. Accessed 31/05/2020, 2020.
17. Clinical and Laboratory Standards Institute. M100: Performance Standards for Antimicrobial Susceptibility Testing. Published 2020. Accessed 01/09/2020, 2020.
18. Beyar-Katz O, Dickstein Y, Borok S, Vidal L, Leibovici L, Paul M. Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer. The Cochrane database of systematic reviews. 2017;6(6):CD003914.
19. Karandikar MV, Milliren CE, Zaboulian R, et al. Limiting Vancomycin Exposure in Pediatric Oncology Patients With Febrile Neutropenia May Be Associated With Decreased Vancomycin-Resistant Enterococcus Incidence.J Pediatric Infect Dis Soc. 2020;9(4):428-436.
20. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011;52(4):427-431.
21. Kennedy HF, Gemmell CG, Bagg J, Gibson BE, Michie JR. Antimicrobial susceptibility of blood culture isolates of viridans streptococci: relationship to a change in empirical antibiotic therapy in febrile neutropenia. J Antimicrob Chemother. 2001;47(5):693-696.
22. Dulanto Chiang A, Sinaii N, Palmore TN. Risk Factors for Viridans Group Streptococcal Bacteremia in Neutropenic and Non-neutropenic Patients: A Single Center Case-Case-Control Study. Open Forum Infect Dis. 2018;5(1):ofx260.